GSK (NYSE:GSK) & TherapeuticsMD (NASDAQ:TXMD) Head to Head Analysis

TherapeuticsMD (NASDAQ:TXMD) and GSK (NYSE:GSK) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares TherapeuticsMD and GSK”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	7.70	-$570,000.00	$0.02	100.50
GSK	$43.07 billion	2.19	$7.54 billion	$3.20	14.54

GSK has higher revenue and earnings than TherapeuticsMD. GSK is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

TherapeuticsMD has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for TherapeuticsMD and GSK, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
GSK	2	7	1	1	2.09

GSK has a consensus price target of $56.50, indicating a potential upside of 21.39%. Given GSK’s stronger consensus rating and higher possible upside, analysts plainly believe GSK is more favorable than TherapeuticsMD.

Institutional & Insider Ownership

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares TherapeuticsMD and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
GSK	14.56%	43.23%	11.60%

Summary

GSK beats TherapeuticsMD on 11 of the 15 factors compared between the two stocks.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.